Consult the medical resource doctors trust

UpToDate is one of the most respected medical information resources in the world, used by over 360,000 doctors and thousands of patients to find answers to medical questions.

  • Content written by a faculty of over 4,000 physicians from leading medical institutions
  • Unbiased: free of advertising or pharmaceutical funding
  • Evidence-based treatment recommendations
  • Continuously updated to incorporate new medical findings

Physiology of cholecystokinin

INTRODUCTION

Cholecystokinin (CCK) is the major hormone responsible for gallbladder contraction and pancreatic enzyme secretion. CCK, like other gastrointestinal hormones, is produced in discrete endocrine cells that line the mucosa of the small intestine [1]. It is also found in the central nervous system and peripheral nerves innervating the intestine. In these locations, CCK probably functions as a neurotransmitter.

The original discovery of CCK in 1928 was based upon the observation that a substance within intestinal extracts stimulated gallbladder contraction in dogs (hence the name cholecystokinin). In 1943, a similar extract (which has been called pancreozymin) was noted to stimulate pancreatic enzyme secretion. However, purification of the hormone and determination of its amino acid sequence showed that the actions on the gallbladder and pancreas were due to the same hormone [2].

Advances in protein biochemistry, molecular biology, and the development of specific CCK receptor antagonists have increased our understanding of the physiologic and potential pathophysiologic actions of CCK. In humans, physiologic properties of CCK include the ability to stimulate gallbladder contraction, increase pancreatic enzyme secretion, delay gastric emptying, potentiate insulin secretion, and regulate food intake (table 1). In addition, CCK regulates bowel motility and has growth promoting effects on the pancreas in certain animals [3,4].

MOLECULAR FORMS

A number of molecular forms of CCK have been identified in brain, intestine, and blood of experimental animals and humans. The original form of CCK purified was a tritriacontapeptide (CCK-33) [5]. CCK is produced from a single gene, and different molecular forms are the result of posttranslational processing. Molecular forms ranging in size from 4 to 83 amino acids have been identified in tissue and blood with the predominant molecular form being CCK-58, and less commonly CCK-8 and CCK-33. (See "Synthesis, secretion, and regulation of gastrointestinal peptides".)

CCK possesses a five amino acid sequence at the carboxyl terminus that is identical to that of gastrin (graph 1). The carboxyl terminus confers the biologic activity of CCK; as a result, gastrin has weak CCK-like activity and CCK has weak gastrin-like activity. The amino acid sequence similarity has also made assays for CCK difficult, since antibodies specific for the biologically active end of the molecule often crossreact with gastrin, which circulates in the blood at concentrations 10 to 100 times greater than that of CCK [6]. (See "Physiology of gastrin".)

To continue reading this article you need to subscribe.

Read the rest of this article and others like it

The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use (click here) ©2009 UpToDate, Inc.
References Top
  1. Polak, J, Pearse, A, Bloom, S, et al. Identification of cholecystokinin-secreting cells. Lancet 1975; 2:1016.
  2. Jorpes, E, Mutt, V. Cholecystokinin and pancreozymin, one single hormone?. Acta Physiol Scand 1966; 66:196.
  3. Mutt, V. Secretin and cholecystokinin. In: Gastrointestinal Hormones, Mutt, V (Ed), Academic Press, San Diego 1988. p.251.
  4. Liddle, RA. Cholecystokinin. In: Gut Peptides: Biochemistry and Physiology, Walsh, JH, Dockray, GJ (Eds), Raven Press, New York 1994. p.175.
  5. Mutt, V, Jorpes, JE. Structure of porcine cholecystokinin-pancreozymin. 1. Cleavage with thrombin and with trypsin. Eur J Biochem 1968; 6:156.
  6. Rehfeld, JF. Cholecystokinin. In: Handbook of Physiology: The Gastrointestinal System, Vol II. Neural and Endocrine Biology, Makhlouf, GM (Ed), Oxford University Press, New York 1989. p.337.
  7. Meyer, DK, Protopapas, Z. Studies on cholecystokinin-containing neuronal pathways in rat cerebral cortex and striatum. Ann N Y Acad Sci 1985; 448:133.
  8. Kopin, AS, Mathes, WF, McBride, EW. et al. The cholecystokinin-A receptor mediates inhibition of food intake yet is not essential for maintenance of body weight. J Clin Invest 1999; 103:383.
  9. Wank, SA, Harkins, R, Jensen, RT, et al. Purification, molecular cloning, and functional expression of the cholecystokinin receptor from rat pancreas. Proc Natl Acad Sci U S A 1992; 89:3125.
  10. Kopin, AS, Lee, YM, McBride, EW, et al. Expression cloning and characterization of the canine parietal cell gastrin receptor. Proc Natl Acad Sci U S A 1992; 89:3605.
  11. Takiguchi, S, Takata, Y, Funakoshi, A, et al. Disrupted cholecystokinin type-A receptor (CCKAR) gene in OLETF rats. Gene 1997; 197:169.
  12. Langhans, N, Rindi, G, Chiu, M, et al. Abnormal gastric histology and decreased acid production in cholecystokinin-B/gastrin receptor-deficient mice. Gastroenterology 1997; 112:280.
  13. Green, GM, Lyman, RL. Feedback regulation of pancreatic enzyme secretion as a mechanism for trypsin inhibitor-induced hypersecretion in rats. Proc Soc Exp Biol Med 1972; 140:6.
  14. Owyang, C, Louie, DS, Tatum, D. Feedback regulation of pancreatic enzyme secretion. Suppression of cholecystokinin release by trypsin. J Clin Invest 1986; 77:2042.
  15. Spannagel, AW, Green, GM, Guan, D, et al. Purification and characterization of a luminal cholecystokinin-releasing factor from rat intestinal secretion. Proc Natl Acad Sci U S A 1996; 93:4415.
  16. Herzig, KH, Schon, I, Tatemoto, K, et al. Diazepam binding inhibitor is a potent cholecystokinin-releasing peptide in the intestine. Proc Natl Acad Sci U S A 1996; 93:7927.
  17. Liddle, RA. Regulation of cholecystokinin secretion by intraluminal releasing factors. Am J Physiol 1995; 269:G319.
  18. Owyang, C, Logsdon, CD. New insights into neurohormonal regulation of pancreatic secretion. Gastroenterology 2004; 127:957.
  19. Liddle, RA, Morita, ET, Conrad, CK, Williams, JA. Regulation of gastric emptying in humans by cholecystokinin. J Clin Invest 1986; 77:992.
  20. Moran, TH, Ameglio, PJ, Peyton, HJ, et al. Blockade of type A, but not type B, CCK receptors postpones satiety in rhesus monkeys. Am J Physiol 1993; 265:R620.
  21. Moran, TH, Sawyer, TK, Seeb, DH, et al. Potent and sustained satiety actions of a cholecystokinin octapeptide analogue. Am J Clin Nutr 1992; 55:286S.
  22. Jordan, J, Greenway, FL, Leiter, LA, et al. Stimulation of cholecystokinin-A receptors with GI181771X does not cause weight loss in overweight or obese patients. Clin Pharmacol Ther 2008; 83:281.
  23. Roses, AD. Stimulation of cholecystokinin-A receptors with Gl181771X: a failed clinical trial that did not test the pharmacogenetic hypothesis for reduction of food intake. Clin Pharmacol Ther 2009; 85:362.
  24. Zerbib, F, Bruley Des Varannes, S, Scarpignato, C. Endogenous cholecystokinin in postprandial lower esophageal sphincter function and fundic tone in humans. Am J Physiol 1998; 275:G1266.
  25. Smith, JP, Solomon, TE, Bagheri, S, Kramer, S. Cholecystokinin stimulates growth of human pancreatic adenocarcinoma SW-1990. Dig Dis Sci 1990; 35:1377.
  26. Staley, J, Jensen, RT, Moody, TW. CCK antagonists interact with CCK-B receptors on human small cell lung cancer cells. Peptides 1990; 11:1033.
  27. Heinricher, MM, Neubert, MJ. Neural basis for the hyperalgesic action of cholecystokinin in the rostral ventromedial medulla. J Neurophysiol 2004; 92:1982.
  28. Doty, JE, Pitt, HA, Porter-Fink, V, Denbesten, L. Cholecystokinin prophylaxis of parenteral nutrition-induced gallbladder disease. Ann Surg 1985; 201:76.
  29. Sitzmann, JV, Pitt, HA, Steinborn, PA, et al. Cholecystokinin prevents parenteral nutrition induced biliary sludge in humans. Surg Gynecol Obstet 1990; 170:25.
  30. Khan, IU, Beck-Sickinger, AG. Targeted tumor diagnosis and therapy with peptide hormones as radiopharmaceuticals. Anticancer Agents Med Chem 2008; 8:186.
  31. Wolkowitz, OM, Gertz, B, Weingartner, H, et al. Hunger in humans induced by MK-329, a specific peripheral-type cholecystokinin receptor antagonist. Biol Psychiatry 1990; 28:169.
  32. Satake, K, Kimura, K, Saito, T. Therapeutic effects of loxiglumide on experimental acute pancreatitis using various models. Digestion 1999; 60 Suppl 1:64.
  33. Ochi, K, Harada, H, Satake, K. Clinical evaluation of cholecystokinin-A- receptor antagonist (loxiglumide) for the treatment of acute pancreatitis. A preliminary clinical trial. Study Group of Loxiglumide in Japan. Digestion 1999; 60 Suppl 1:81.
  34. Wang, RY, Ashby, CR Jr. Biological actions of CCK in the central nervous system. In: CCK Antagonists in Gastroenterology, Adler, G, Beglinger, C (Eds), Springer-Verlag, Berlin-Heidelberg 1991. p.44.
  35. Beltinger, J, Hildebrand, P, Drewe, J, et al. Effects of spiroglumide, a gastrin receptor antagonist, on acid secretion in humans. Eur J Clin Invest 1999; 29:153.
  36. Geracioti, TD Jr, Liddle, RA. Impaired cholecystokinin secretion in bulimia nervosa. N Engl J Med 1988; 319:683.
  37. Calam, J, Ellis, A, Dockray, GJ. Identification and measurement of molecular variants of cholecystokinin in duodenal mucosa and plasma. Diminished concentrations in patients with celiac disease. J Clin Invest 1982; 69:218.
  38. Keel, PK, Wolfe, BE, Liddle, RA, et al. Clinical features and physiological response to a test meal in purging disorder and bulimia nervosa. Arch Gen Psychiatry 2007; 64:1058.
  39. Srivastava, A, Pandey, SN, Dixit, M, et al. Cholecystokinin receptor A gene polymorphism in gallstone disease and gallbladder cancer. J Gastroenterol Hepatol 2008; 23:970.
  40. Miller, LJ, Holicky, EL, Ulrich, CD, Wieben, ED. Abnormal processing of the human cholecystokinin receptor gene in association with gallstones and obesity. Gastroenterology 1995; 109:1375.
  41. Miyasaka, K, Takiguchi, S, Funakoshi, A. Cholecystokinin 1A receptor polymorphisms. Curr Top Med Chem 2007; 7:1205.
white circle LOG IN
white circle DEMO